Aging of the brain is characterized by deleterious processes at various levels including cellular/molecular and ...

Lu]Lu-PSMA-617 radiopharmaceutical therapy has been approved for the treatment of men with metastatic castration-resistant ...

Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease marked by fibrosis, strictures, and a high risk for developing cholangiocarcinoma (CCC). Recognition of CCC in PSC remains a ...

Journal of Nuclear Medicine September 2025, jnumed.125.270807; DOI: https://doi.org/10.2967/jnumed.125.270807 ...

Journal of Nuclear Medicine September 2025, jnumed.125.269688; DOI: https://doi.org/10.2967/jnumed.125.269688 ...

Journal of Nuclear Medicine August 2025, jnumed.125.269721; DOI: https://doi.org/10.2967/jnumed.125.269721 ...

Journal of Nuclear Medicine August 2025, jnumed.125.270317; DOI: https://doi.org/10.2967/jnumed.125.270317 ...

Journal of Nuclear Medicine August 2025, jnumed.125.270318; DOI: https://doi.org/10.2967/jnumed.125.270318 ...

Currently, PET scanner validation phantoms, methods, and acceptance criteria for clinical trials are not standardized. This ...

This review explores the role of PET in imaging immune activation, particularly in oncology. 18 F-FDG is widely used for assessing treatment response to immunotherapies and can demonstrate unique ...

Radiopharmaceutical therapy (RPT) is entering a new era of personalization, driven by advances in molecular imaging, radiopharmaceutical development, and a growing body of clinical evidence linking ...

Nectin-4 is an overexpressed biomarker in 60%–70% of triple-negative breast cancer (TNBC) cases and an ideal target for radiotherapy and PET imaging. In this study, theranostic radioimmunoconjugates ...